Hamlet Pharma is increasing its focus on the company’s digital channels, to provide easier access for shareholders and the public. So far, this effort includes an updated website, a digital meeting with shareholders and the recruitment of media strategist Erik Cronqvist.
On November 30th, a digital zoom meeting was held as a substitute for the presentations that normally take place at the Annual general assembly. We would like to thank the large number of investors, who attended the meeting for their interest and participation in the conversation. The meeting was recorded and has been posted to the Hamlet Pharma website.
Hamlet Pharma has also updated the website, to reorganize its contents and help users find the latest news and access other relevant information. We have also added content about the scientific background and the company vision.
Welcome to visit us at www.hamletpharma.com
We would also like to take the opportunity to welcome our media strategist Mr. Erik Cronqvist, who will manage our digital media platforms. Erik is an interaction designer by training and has extensive experience with international digital media, working in China, Portugal and the USA. After living and working in Beijing, China, his Chinese is fluent.
For more information, please contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46 709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.
This project is funded from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954360.